Items where authors include "Wheater, M."

Article

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30 (2). pp. 317-324. ISSN 0923-7534

Arriola, E., Wheater, M., Galea, I. et al. (13 more authors) (2016) Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. Journal of Thoracic Oncology, 11 (9). pp. 1511-1521. ISSN 1556-0864

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931